Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.62 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.60 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.60 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL340456 | 0.88 | ALDH1A1 (0.59) | KMOPLOD2PLOD3PLOD1MAPT | |
| SCHEMBL10743626 | 0.84 | PLOD2 (0.60) | PLOD2PLOD3PLOD1MAPTALDH1A1 | |
| SCHEMBL340946 | 0.81 | KMO (0.68) | KMOPLOD2PLOD3PLOD1ALDH1A1 | |
| SCHEMBL3831932 | 0.81 | KMO (0.68) | KMOPLOD2PLOD3PLOD1MAPT | |
| SCHEMBL15567860 | 0.81 | GSK3B (0.70) | KMOPLOD2PLOD3PLOD1MAPT | |
| SCHEMBL3495303 | 0.77 | KMO (0.68) | KMOPLOD2PLOD3PLOD1MAPT | |
| SCHEMBL65857 | 0.77 | KMO (1.00) | KMOPLOD2PLOD3PLOD1MAPT | |
| SCHEMBL303084 | 0.77 | KMO (0.77) | KMOPLOD2PLOD3PLOD1MAPT | |
| SCHEMBL30634127 | 0.77 | KMO (1.00) | KMOPLOD2PLOD3PLOD1MAPT | |
| SCHEMBL28692105 | 0.76 | PLOD2 (0.67) | KMOPLOD2PLOD3PLOD1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112348-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2017-01-04 | — | — | EP | disclosed |
| CN-103347859-B | Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives | EFFICIENT PHARMA MANAGEMENT CORP. (CN) | 2015-12-02 | — | — | CN | disclosed |
| CN-103347859-A | Synthesis and Anticancer Activity of Aryl and Heteroaryl Quinoline Derivatives | EFFICIENT PHARMA MAN CORP | 2013-10-09 | — | — | CN | disclosed |
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| EP-2593435-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Tairx, Inc. (TW) | 2013-05-22 | — | — | EP | disclosed |
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | Efficient Pharma Management Corporate (TW) | 2012-01-19 | — | — | US | disclosed |
| WO-2012009519-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | EFFICIENT PHARMA MANAGEMENT CORP. (TW) | 2012-01-19 | — | — | WO | disclosed |
| US-4656267-A | RENAL VASODILATORS, CARDIOVASCULAR AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-04-07 | — | — | US | disclosed |
| US-4555571-A | Substituted 2(1H)-quinazolinone-1-alkanoic acids and esters | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-11-26 | — | — | US | disclosed |
| EP-0138491-A2 | Substituted 2(1H)-quinazolinone-1-alkanoic acids and esters | ORTHO PHARMACEUTICAL CORPORATION (US) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015908-A1 | SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES | SLC22A8, ABCC8, CYP2C8 | KMO 490/4885PLOD2 3794/4885PLOD3 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.